DVA Company Profile and Key Details

Q: Who are the executives of DVA?

Dr. Jeffrey Allen GiullianChief Medical Officer of Kidney CareMs. Kathleen Alyce WatersChief Legal & Public Affairs OfficerMr. James O. HeartyChief Compliance OfficerMr. Javier J. RodriguezChief Executive Officer & Executive DirectorMr. Joel AckermanChief Financial Officer & TreasurerMr. Michael David StaffieriChief Operating Officer of Kidney CareMr. Atul MathurExecutive Vice President of Global OperationsMr. Jim GustafsonVice President of Investor RelationsMr. John D. WinstelChief Accounting OfficerDr. Abdulkareem Alsuwaida FRCPC, M.D., MScChief Medical Officer - Saudi OperationsMr. Kenneth Gardner SmithChief People OfficerMr. Misha PalecekChief Transformation Officer of HealthCare PartnersDr. Dinesh M. Kumar M.D.Chief Medical Officer

NYSE : DVA

DaVita

$137.64

-3.19-2.27%

At Close 4:00 PM

63.24

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

DaVita Inc. (DVA) stock declined over -2.27%, trading at $137.64 on NYSE, down from the previous close of $140.83. The stock opened at $140.00, fluctuating between $136.22 and $140.97 in the recent session.

Stock Snapshot

140.83

Prev. Close

9.72B

Market Cap

136.22

Day Low

14.47

P/E Ratio

9.51

EPS (TTM)

16.52

Cash Flow per Share

140

Open

70.6M

Number of Shares

140.97

Day High

95.11%

Free Float in %

11.69

Book Value

1.33M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 09, 2026	140.00	141.50	136.19	137.64	1.49M
Feb 06, 2026	149.00	151.42	139.54	140.83	2.25M
Feb 05, 2026	143.68	150.45	142.51	149.22	2.22M
Feb 04, 2026	136.06	147.60	135.90	142.06	3.04M
Feb 03, 2026	128.00	139.86	125.00	134.73	4.81M
Feb 02, 2026	109.06	111.33	108.88	111.19	2.36M
Jan 30, 2026	107.12	109.50	105.41	109.34	1.08M
Jan 29, 2026	106.00	107.76	105.51	107.24	1.15M
Jan 28, 2026	104.75	106.85	104.06	105.88	709.47K
Jan 27, 2026	106.79	106.96	105.03	105.61	750.09K
Jan 26, 2026	108.40	108.61	106.70	107.51	583.31K
Jan 23, 2026	108.64	109.16	107.40	108.12	1.03M
Jan 22, 2026	107.33	110.43	107.20	109.17	903.28K
Jan 21, 2026	103.90	106.69	103.90	106.30	970.25K
Jan 20, 2026	103.91	105.12	103.48	103.93	921.9K
Jan 16, 2026	104.94	106.32	104.20	104.74	649.78K
Jan 15, 2026	103.25	106.38	102.26	105.84	948.63K
Jan 14, 2026	104.00	104.86	101.00	103.87	2.11M
Jan 13, 2026	110.00	110.10	104.24	104.47	1.08M
Jan 12, 2026	111.49	111.72	109.59	110.10	565.92K

Contact Details

Denver, CO 80202

United States

https://www.davita.com 720 631 2100

About Company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Stock Peers

HCA

-4.15-0.83%

HCA Healthcare, Inc.$497.54 CHE

0.43+0.10%

Chemed Corporation$448.17 UHS

-5.62-2.57%

Universal Health Services, Inc.$212.94 THC

-8.41-4.18%

Tenet Healthcare Corporation$192.96 EHC

0.77+0.73%

Encompass Health Corporation$106.16 USPH

-1.1-1.29%

U.S. Physical Therapy, Inc.$84.48 SOLV

-0.05-0.06%

Solventum Corporation$78.07 BKDT

-2.09-2.62%

Brookdale Senior Living Inc. 7.$77.60 SNDA

0.48+1.40%

Sonida Senior Living, Inc.$34.67 FMS

-0.19-0.79%

Fresenius Medical Care AG & Co. KGaA$23.89

Company Overview

DaVita Inc. (NYSE:DVA) closed at $137.64 USD, losing -$3.19 (-2.27%) from the previous close of $140.83. The stock is currently mid-range between its 52-week high and low $101.00 and $178.38. With a market capitalization of about $9.72 billion, DaVita Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 1.07 million shares, in line with its 52-week average. Headquartered in Denver, CO, DaVita Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Javier J. Rodriguez, the company employs approximately 76,000 people and listed since October 31, 1995. DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 19.28%, SMA50 18.66%, SMA200 5.91%). The stock’s 14-day RSI is 67.69 (firm momentum), while the ATR of 5.89 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -22.84% below its high and over 36.28% above its low. Average 10-day trading volume of 2.47 million shares is significantly above the 3-month average of 1.06 million, indicating heightened recent market interest.

Valuation Metrics

DaVita Inc. trades at a P/E ratio of 16.34, slightly below the S&P 500 average, with a price-to-sales ratio of 0.74 and a price-to-book ratio of -18.29 indicating negative book value, which may reflect financial stress. The P/FCF stands at 7.45, also above market averages.

Dividend & Fair Value

DaVita Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $419.04. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

DaVita Inc. generated EPS of $9.91 over the past year. Five-year average earnings growth is 9.03%. Wall Street analysts project EPS growth of 20.99% annually over the next five years. The latest quarter delivered EPS of $2.51. The next quarter is forecast at $2.34. Next year's EPS is expected at $9.76. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 6 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $190.00 to $133.00. The high target offers 38.04% upside. The low target suggests -3.37% downside. The mean target is $155.25. This offers 12.79% upside. DaVita Inc. earnings surprise history is a mixed track record. The quarter that ended October 29, 2025, missed forecasts by -20.82%. The prior quarter beat by 9.26%. Over the last six quarters, Apple has recorded several small beats. These include 4.86% in August 06, 2024.

Shareholding & Insider Activity

DaVita Inc. has 71.50 million shares outstanding. The public float is 35.70 million shares, elevated short interest at 18.26% of float. This equals 6.43 million shares. The short ratio is 7.57 days. Institutional investors hold 103.83% of the float. Insiders own 49.99%. BERKSHIRE HATHAWAY INC holds 30.10 million shares, WESCHLER, R. TED has 1.99 million shares and Rodriguez Javier has 837.84 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.06 million shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, DaVita generated $12.14B in revenue, or $130.28 per share. Gross margin was 25.33%, operating margin 13.19%, and net profit margin 5.70%. Returns are modest, with ROA at 3.92% and ROE at 65.48%.
On valuation metrics, DaVita trades at a P/E of 16.34, P/S of 0.74 and P/B of -18.29. The current ratio is 1.29 and quick ratio is 1.24. Operationally, the company’s inventory turnover is 56.46 and cash conversion cycle is 44.81 days. Debt-to-equity is -18.95, supported by a cash flow-to-debt ratio of 0.15.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, DaVita posted revenue of $12.14B, down slightly from $11.61B in the prior quarter. Gross profit was $3.07B (margin 25.33%). Operating income was $1.60B (margin 13.2%). Net income was$691.54M (EPS $7.62).
The company ended the quarter with $476.24M in cash and short-term investments, a total debt of $11.12B, and net debt of $10.65B. Total assets were $17.62B, with equity of $2.74B. Financials further reflected stability, with operating cash flow of $2.06B, free cash flow of $1.50B, and capital expenditures of - $567.99M.

Price Forecast & Outlook

Our AI price prediction model suggests that DaVita Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.42%, with price expected at $140.97 by February 23, 2026, within a range of $129.52 to $153.17 3-Month Outlook: Projected fall of -13.35%, reaching $119.26 by May 07, 2026, with a range of $114.90 to $123.18. 1-Year Outlook: Projected gain of 13.83%, with price at $156.67 by February 09, 2027, within a range of $148.64 to $164.30.

Key Takeaways

DaVita Inc. (NYSE:DVA) shares are flat -8.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows DaVita Inc. trading at a premium to the broader market with a P/E of 16.34. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $123.33, suggesting -10.4% downside. Our AI forecast model points to short-term strength (2.42% over two weeks), a medium-term fall (-13.35% over three months), and a longer-term gain (13.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current DaVita Inc. (DVA) stock price?

DaVita Inc. (NYSE: DVA) stock price is $137.64 in the last trading session. During the trading session, DVA stock reached the peak price of $140.97 while $136.22 was the lowest point it dropped to. The percentage change in DVA stock occurred in the recent session was -2.27% while the dollar amount for the price change in DVA stock was - $3.19.

DVA's industry and sector of operation?

The NYSE listed DVA is part of Medical - Care Facilities industry that operates in the broader Healthcare sector. DaVita Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DVA?

Dr. Jeffrey Allen Giullian
Chief Medical Officer of Kidney Care
Ms. Kathleen Alyce Waters
Chief Legal & Public Affairs Officer
Mr. James O. Hearty
Chief Compliance Officer
Mr. Javier J. Rodriguez
Chief Executive Officer & Executive Director
Mr. Joel Ackerman
Chief Financial Officer & Treasurer
Mr. Michael David Staffieri
Chief Operating Officer of Kidney Care
Mr. Atul Mathur
Executive Vice President of Global Operations
Mr. Jim Gustafson
Vice President of Investor Relations
Mr. John D. Winstel
Chief Accounting Officer
Dr. Abdulkareem Alsuwaida FRCPC, M.D., MSc
Chief Medical Officer - Saudi Operations
Mr. Kenneth Gardner Smith
Chief People Officer
Mr. Misha Palecek
Chief Transformation Officer of HealthCare Partners
Dr. Dinesh M. Kumar M.D.
Chief Medical Officer

How DVA did perform over past 52-week?

DVA's closing price is 36.28% higher than its 52-week low of $101.00 where as its distance from 52-week high of $178.38 is -22.84%.

How many employees does DVA have?

Number of DVA employees currently stands at 76,000.

Link for DVA official website?

Official Website of DVA is: https://www.davita.com

How do I contact DVA?

DVA could be contacted at phone 720 631 2100 and can also be accessed through its website. DVA operates from 2000 16th Street, Denver, CO 80202, United States.

How many shares of DVA are traded daily?

DVA stock volume for the day was 1.33M shares. The average number of DVA shares traded daily for last 3 months was 1.07M.

What is the market cap of DVA currently?

The market value of DVA currently stands at $9.72B with its latest stock price at $137.64 and 70.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	76000
Beta	1.01
Sales or Revenue	$12.14B
5Y Sales Change%	1.002%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Care Facilities

DVA Company Profile and Key Details

DaVita

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook